Actinium Pharmaceuticals, Inc. — FY2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. This is an annual filing, not a standalone fourth-quarter report. Filed March 16, 2018.
Business context
Actinium is a clinical-stage biopharmaceutical company developing antibody radio-conjugates (ARCs) for bone-marrow conditioning before transplant and for cancer treatment. It had no approved products and generated no commercial revenue. Its lead candidate, Iomab-B, was in a pivotal Phase 3 trial for older patients with relapsed or refractory AML; its lintuzumab-actinium-225 CD33 program included Phase 2 Actimab-A in AML and Phase 1 Actimab-M in multiple myeloma. A Phase 2 Actimab-MDS trial and a Phase 1 Actimab-A/CLAG-M trial were planned for 2018. The company also pursued its preclinical AWE technology platform.
Financial results and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $17.7 million | $17.8 million |
| General and administrative expense | $9.2 million | $9.0 million |
| Operating loss | $26.9 million | $26.8 million |
| Net loss | $26.6 million | $24.3 million |
| Net loss per share, basic and diluted | $0.40 | $0.50 |
| Operating cash used | $21.6 million | $20.8 million |
| Cash and cash equivalents at year-end | $17.4 million | $20.5 million |
| Total assets / liabilities | $18.3 million / $4.7 million | $22.5 million / $4.5 million |
Net loss widened by $2.3 million, chiefly because the gain from revaluing derivative liabilities fell to $0.3 million from $2.5 million and the company incurred one-time charges for former employees. R&D spending was nearly flat year over year; G&A increased modestly. Operating cash use rose by about $0.8 million. No operating margin is meaningful because revenue was zero. The balance sheet reports no debt; liabilities primarily comprised accounts payable, accrued expenses and derivative liabilities. The company said year-end cash was sufficient to fund operations for the next 12 months, while also warning it would need additional financing to continue development and commercialization.
Material changes and financing
- In August 2017, Actinium raised approximately $15.0 million net in an underwritten offering of 21.5 million shares and warrants for 18.275 million shares, exercisable at $1.05.
- ATM sales generated approximately $3.8 million net in 2017. Total 2017 net financing cash flow was $18.8 million.
- Common shares outstanding at December 31, 2017 were 80.1 million, up from 55.8 million a year earlier. Outstanding warrants increased to 25.7 million from 9.0 million.
- After year-end, a March 2018 rights offering issued 30.1 million shares plus Series A and B warrants, producing approximately $13.9 million net proceeds. The filing reported 110.2 million common shares outstanding as of March 16, 2018.
- Total stockholders’ equity declined to $13.7 million from $18.0 million. Accumulated deficit reached $163.2 million.
Outlook, commentary and principal risks
- Management planned to advance the Iomab-B Phase 3 trial and manufacturing readiness, progress Actimab-A and Actimab-M, and initiate the planned MDS and CLAG-M studies in 2018. These are plans, not assured outcomes.
- Preliminary Actimab-A Phase 2 data presented in December 2017 showed objective responses in 9 of 13 evaluable patients and a median 98% bone-marrow blast reduction. Myelosuppression occurred in all patients and lasted longer than desirable for this medically unfit population; the dose was reduced from 2.0 to 1.5 microcuries/kg on Days 1 and 8. These early results do not establish efficacy or approval.
- For the planned Actimab-MDS study, management anticipated a 50–80 patient, single-arm Phase 2 trial and an FDA regulatory-pathway discussion in the first half of 2018. The filing describes the study as planned, not commenced.
- Actinium depends on future financing, with potential dilution or the need to delay, reduce or abandon programs. It has no recurring revenue and expects continued losses.
- Key development risks include clinical failure or delays, patient enrollment, regulatory uncertainty, manufacturing and contractor dependence, and limited availability of actinium-225. The Oak Ridge National Laboratory supply contract ran through 2018 and required renewal; management expected renewal but gave no assurance.
- Intellectual-property risks include the company’s disclosure that key lintuzumab patents had likely expired and that Iomab-B lacked issued or pending patents covering the antibody or composition as a whole. Licensing obligations include potential milestones and royalties.
- The company reported no material legal proceedings. Management and the auditor concluded internal control over financial reporting was effective; the auditor gave an unqualified opinion on the financial statements.
- The filing reported that no dividends were expected in the foreseeable future. Common-stock price ranged from $0.54 to $1.58 during 2017; the March 14, 2018 closing price was $0.43.
Most important facts for investors to verify
- Current cash runway and spending after the March 2018 rights offering, including the effects of warrant exercises and further financing needs.
- Enrollment, timing, endpoints and eventual results of the pivotal Iomab-B Phase 3 SIERRA trial and the FDA’s requirements for a potential BLA.
- Whether the 2018 Actimab-MDS and Actimab-A/CLAG-M trials began as planned, and how later data compare with the preliminary Actimab-A results and observed myelosuppression.
- Reliable, scalable supply of actinium-225 and iodine-131, manufacturing readiness, and any impact of supplier or contract-manufacturer delays.
- Patent scope, remaining exclusivity, license milestones and royalties, and the practical protection available for Iomab-B and the CD33 program.
- Fully diluted share count and potential dilution from outstanding warrants, options and the 2018 rights offering.